PARIS, July 29, 2022--(BUSINESS WIRE)--Regulatory News:
Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO) (Paris:ALONX) (NASDAQ OMX:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced the availability of the preparatory documents for its Combined General Meeting of August 17, 2022.
In order to submit their votes, shareholders may, in accordance with the procedures described in the notice of meeting published in the BALO on July 13, 2022:
attend the meeting in person;
vote by mail, using a voting form;
or by giving a proxy to the Chairman of the General Meeting or to a third party.
All documents related to this general meeting are available on the Company's website, in the General Meetings section, in particular the report of the Board of Directors, which details the aims and consequences of the delisting of the Company from the Nasdaq First North market in Copenhagen, as well as Frequently asked questions.
If you have any questions, please contact the Investor Relations team by e-mail at the dedicated address: email@example.com.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.
AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe in combination with other treatment modalities in difficult-to-treat solid tumors.
OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005438/en/
+33 1 45 58 76 00
+33 1 44 71 94 98
Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
+33 1 44 71 94 92